Lewis Karen's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Jan 17, 2024
- Accession no.
- 0001127602-24-001440
- Filed
- Jan 17, 2024
- Trade date
- Jan 16, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $109.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lewis KarenCIK 0001814304 | Officer (Chief People Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 16, 2024 | Common Stock | AGrant or awardAcquired | +16,963 | $0.00 | $0 | 58,569 | Direct | |
| Jan 16, 2024 | Common Stock | SSaleDisposed | −1,632 | $66.81 | −$109,033.92 | 56,937 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 16, 2024 | Common Stock | AGrant or awardAcquired | +24,666 | $66.30 | +$1,635,355.8 | 24,666 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.